Teva to acquire Emalex for $700M, adding ecopipam for pediatric Tourette syndrome after positive Phase 3 data and planned NDA submission in 2H 2026.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Teva Pharmaceuticals announced a definitive agreement on April 29, 2026, to acquire Emalex Biosciences, including its lead asset ecopipam. Positive Phase 3 data for ecopipam in children with Tourette syndrome showed statistically significant results on the primary efficacy endpoint of time to relapse (p = 0.0084).
Emalex plans to submit a New Drug Application (NDA) in the second half of 2026.
Under the deal, Teva will pay $700 million upfront upon closing. Emalex shareholders may receive up to $200 million in future commercial milestone payments, plus royalties on global net sales of ecopipam, pending regulatory approval. The transaction awaits customary closing conditions, including regulatory approvals, with closure expected by Q3 2026. Teva will fund the upfront payment from cash on hand and aims to offset near-term margin dilution while meeting its 2027 financial targets.
Richard Francis, President and Chief Executive Officer of Teva, stated: “This advances our Pivot to Growth strategy through focused, capital-efficient agreements that expand our late-stage innovative pipeline and commercial portfolio. There is an unmet need in Tourette syndrome, and with our neuroscience expertise, we are positioned to advance this first-in-class compound.”
Eric Messner, Chief Executive Officer of Emalex, commented: “This reflects years of work to advance a first-in-class therapy for Tourette syndrome patients needing better options. Teva’s global scale and neuroscience leadership will help ecopipam reach patients quickly and broadly.”
Jeff Aronin, CEO of Paragon Biosciences (which founded Emalex) and Emalex Chairman, added: “We advanced ecopipam to late-stage readiness with speed and precision. Teva brings the scale and expertise to execute globally and accelerate patient access.”
About Tourette Syndrome
Tourette syndrome is a chronic neurodevelopmental disorder that starts in childhood, typically between ages 5 and 10. It features involuntary motor and vocal tics that disrupt daily life. Current treatments often target D2 receptors and provide partial control, with side effects limiting use for many patients. In the U.S., ecopipam holds Orphan Drug designation for pediatric patients, as the condition affects fewer than 200,000 people.
About Ecopipam
Ecopipam is a selective dopamine D1 receptor antagonist (targeting D1 and D5 subtypes) in late-stage development for pediatric Tourette syndrome. D1 receptor hypersensitivity may drive repetitive behaviors in the disorder. The Phase 3 study met its primary endpoint in pediatric patients.
Ecopipam also has FDA Fast Track designation. It was generally well-tolerated, with common adverse events including somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%). Unlike approved therapies, ecopipam acts primarily on D1 receptors.
References
About the Writer
Samiksha Vikram Jadhav is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.
